Nivolumab induced myxedema crisis

ConclusionNivolumab can cause immune-mediated endocrinopathies including thyroiditis, hypophysitis, adrenal insufficiency and type 1 diabetes mellitus. High index of suspicion and periodic measurement of thyroid function tests are recommended in patients receiving nivolumab therapy. Our case also suggests that once the myxedema crisis is treated and symptoms are resolved, nivolumab can be safely re-challenged.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research